At UiPath’s Fusion London event, NFU Mutual’s automation lead explains how the UK insurer built a working agentic claims ...

UiPath (NYSE:PATH) declined approximately 6% in today’s session, trading below $12 midday on Thursday. The selloff is ...

Beren Therapeutics P.B.C.®, the parent company of Mandos LLC® and a leader in cholesterol trafficking biology and ...

Celonis evangelist Rudy Kuhn argues that without process intelligence, AI agents are flying blind - and that composability, not another three-year transformation program, is the real key to enterprise ...

UiPath Inc. (NYSE: PATH) has garnered a bullish rating from analyst Scott Berg of Needham, who has placed a “Buy” designation on the stock as of. This recommendation comes with a price target of $15, ...

Chris Ashley, Director of BD & Strategy at UiPath, doesn't mince words about where most organizations actually stand on data ...

UiPath shares have had a tough start to the year, but the company has a big potential opportunity ahead.

UiPath (PATH) heads into its fiscal fourth quarter report today, with investors weighing its history of meeting guidance against softer sector sentiment, fresh healthcare agentic AI launches, and new ...

UiPath is well-positioned to accelerate growth through AI adoption as it leans into agentic services. Client wins and ...

UiPath Inc PATH reported better-than-expected financial results for the fourth quarter of fiscal 2026 after the market close on Wednesday. The company reported revenue of $481.11 million versus ...

On March 12, 2026, investors weighed UiPath’s first full-year profit against slowing growth and divided Wall Street views.

Detailed price information for Uipath Inc Cl A (PATH-N) from The Globe and Mail including charting and trades.